<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10621">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641641</url>
  </required_header>
  <id_info>
    <org_study_id>PINT01</org_study_id>
    <nct_id>NCT00641641</nct_id>
  </id_info>
  <brief_title>The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection</brief_title>
  <acronym>PINT</acronym>
  <official_title>An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the decay characteristics of HIV in the blood of
      patients after taking a combination of anti-HIV drugs, which includes a new class of
      anti-HIV drug, an integrase inhibitor. This study explores how this new combination of
      therapy reduces virus in various compartments of the body and immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label study of 3-years duration. This study will be conducted at 4
      study sites in Sydney, Australia. Sixteen participants will be recruited comprising 8
      participants diagnosed with primary HIV infection (Cohort A) and 8 individuals with chronic
      HIV infection (Cohort B). All patients must be antiretroviral therapy (ART) na√Øve and will
      commence a regimen of combination ART consisting of tenofovir disoproxil fumarate and
      emtricitabine (TDF/FTC; Truvada) plus the integrase inhibitor, raltegravir. Subjects will be
      followed for three years with intensive quantification of both plasma RNA and cell
      associated DNA viral species.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change From Baseline Plasma HIV RNA (Log Copies/mL)</measure>
    <time_frame>12 times within 48 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>change was calculated as the mean of 12 assessments minus the baseline value</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>antiretroviral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + emtricitabine + raltegravir.</intervention_name>
    <description>TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.</description>
    <arm_group_label>antiretroviral therapy</arm_group_label>
    <other_name>TDF</other_name>
    <other_name>FTC</other_name>
    <other_name>RAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years.

          -  Provision of written, informed consent.

          -  Screening plasma HIV RNA &gt; 10,000 copies/mL.

          -  Screening CD4+ T lymphocyte count &gt; 100 x 10^6)/L.

          -  No previous antiretroviral therapy.

          -  Haemoglobin &gt; 115 g/L (female) or &gt; 130 g/L (male).

          -  Absolute neutrophil count &gt; 1 x 10^9/L.

          -  Platelet count &gt; 100 x 10^9/L

          -  Serum bilirubin &lt; 1.5 x ULN.

          -  Serum alkaline phosphatase &lt; 3 X ULN.

          -  Serum aspartate aminotransferase (AST) &lt; 3 X ULN.

          -  Serum alanine aminotransferase (ALT) &lt; 3 X ULN.

          -  Creatinine clearance &gt; 50mL/min (Creatinine clearance (mL/min) =140 - age x weight
             creatinine Multiply the result by 1.2 for men).

        Cohort A: Primary HIV infection:

        Documented acute or early infection diagnosed by:

        Acute infection:

        &lt; 3 bands on Western Blot and any one of: i. positive p24 antigen ii. positive proviral
        DNA

        Early infection:

        i. Positive detuned or BED ELISA result OR ii. Previously negative serology within 6
        months of confirmed positive serology.

        Cohort B: Chronic HIV infection:

        Documented HIV-infection of at least 12 months duration.

        Exclusion Criteria:

          -  Pregnancy or breastfeeding.

          -  Receipt of investigational products within 1 month of study entry.

          -  Receipt of any of the following within 6 months of study entry:

               -  interferon alpha or gamma

               -  oral corticosteroids (inhaled or topical corticosteroids are permitted)

               -  cyclosporin

               -  alkylating agents

               -  other immunosuppressive agents

               -  rifampin

               -  phenytoin

               -  phenobarbital

          -  Documented genotypic (IAS 2007) resistance to tenofovir or emtricitabine from any HIV
             drug resistance test.

          -  Any medications contraindicated with Truvada or raltegravir.

          -  Significant intercurrent illnesses apart from HIV infection such as viral hepatitis
             (diagnosed by core hepatitis B antigen and/or positive hepatitis B PCR or positive
             hepatitis C PCR) or any other condition which in the opinion of the investigator
             would compromise participation in the study.

          -  History of non-traumatic osteoporotic fracture.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Kelleher, MBBS (Hons) PhD, FRACP, FRCPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst, Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407 Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21860347</url>
    <description>Peer reviewed publication of trial results</description>
  </link>
  <results_reference>
    <citation>Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M, Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD; PINT study team. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS. 2011 Nov 13;25(17):2069-78. doi: 10.1097/QAD.0b013e32834b9658. Erratum in: AIDS. 2012 Nov 28;26(18):2425. AIDS. 2012 Jul 17;26(11):1455.</citation>
    <PMID>21860347</PMID>
  </results_reference>
  <results_reference>
    <citation>Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, Baker D, Zaunders JJ, Emery S, Cooper DA, Koelsch KK, Kelleher AD; PINT STUDY TEAM. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS. 2012 Mar 13;26(5):543-50. doi: 10.1097/QAD.0b013e328350fb3c.</citation>
    <PMID>22410637</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>February 28, 2008</firstreceived_date>
  <firstreceived_results_date>April 11, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kirby Institute</investigator_affiliation>
    <investigator_full_name>CSajjadi</investigator_full_name>
    <investigator_title>Central Admin</investigator_title>
  </responsible_party>
  <keyword>Viral compartments</keyword>
  <keyword>integrase inhibitor therapy</keyword>
  <keyword>viral species</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 5 clinical centres in Sydney</recruitment_details>
      <pre_assignment_details>A screening period of less than 42 days prior to commencement of study drugs was employed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug Intervention</title>
          <description>Tenofovir+emtricitabine+raltegravir</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug Intervention</title>
          <description>Tenofovir+emtricitabine+raltegravir</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline Plasma HIV RNA (Log Copies/mL)</title>
        <description>change was calculated as the mean of 12 assessments minus the baseline value</description>
        <time_frame>12 times within 48 weeks.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Intervention</title>
            <description>Tenofovir+emtricitabine+raltegravir</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Plasma HIV RNA (Log Copies/mL)</title>
            <description>change was calculated as the mean of 12 assessments minus the baseline value</description>
            <units>log copies/mL plasma</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" spread="0.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drug Intervention</title>
          <description>Tenofovir+emtricitabine+raltegravir</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited cohort (n=16) of exclusively male participants treated with a licensed regimen of combination antiretroviral therapy with the primary focus being a detailed examination of virus decay characteristics</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sean Emery</name_or_title>
      <organization>University of New South Wales</organization>
      <phone>9385 0900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
